[A20-78] Secukinumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V
Last updated 18.02.2021
Commission awarded on 31.08.2020 by the Federal Joint Committee (G-BA).
Skin and hair
|Children and adolescents from the age of 6 years with moderate to severe plaque psoriasis who are candidates for systemic therapy|
|Added benefit not proven due to lack of suitable study data|
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.